Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Department of Diabetology, Kameoka Municipal Hospital, Kameoka 621-8585, Japan.
Medicina (Kaunas). 2022 Mar 26;58(4):481. doi: 10.3390/medicina58040481.
The BMDs of the lumbar spine, whole femur, and femoral neck and TBS were measured. Change in BMD or TBS was defined as the BMD or TBS at follow-up, performed 1 year after baseline, minus baseline BMD or TBS. This retrospective cohort study included 93 patients, of whom 52 received no medication, 26 received bisphosphonates, and 15 received weekly teriparatide. BMD of the lumbar spine increased in all three groups. There was no change in BMD of the whole femur and femoral neck in the no medication and bisphosphonates groups, whereas the BMD of the whole femur (from 0.73 (0.15) to 0.74 (0.15) g/cm, = 0.011) and femoral neck (from 0.59 (0.16) to 0.60 (0.16) g/cm, = 0.011) in the teriparatide group increased. The change in BMD of the femoral neck (no medication; -0.002 (0.034) g/cm, bisphosphonates; -0.0001 (0.024) g/cm, and teriparatide; 0.017 (0.022) g/cm, = 0.091) or TBS (no medication; -0.007 (0.051), bisphosphonates; -0.058 (0.258), and teriparatide; 0.021 (0.044), = 0.191) in the teriparatide group tended to be higher than that in the other groups, although there was no statistically significant difference. Teriparatide increased the BMD of the femoral neck and TBS in osteoporosis patients with type 2 diabetes mellitus, compared to bisphosphonates and no medication.
本回顾性队列研究纳入了 93 名患者，其中 52 名未接受药物治疗，26 名接受双膦酸盐治疗，15 名接受每周特立帕肽治疗。三组患者腰椎 BMD 均增加。未接受药物治疗和双膦酸盐治疗组的全股骨和股骨颈 BMD 无变化，而特立帕肽组全股骨（从 0.73（0.15）至 0.74（0.15）g/cm，=0.011）和股骨颈（从 0.59（0.16）至 0.60（0.16）g/cm，=0.011）BMD 增加。股骨颈 BMD 变化（未接受药物治疗组：-0.002（0.034）g/cm，双膦酸盐组：-0.0001（0.024）g/cm，特立帕肽组：0.017（0.022）g/cm，=0.091）或 TBS（未接受药物治疗组：-0.007（0.051），双膦酸盐组：-0.058（0.258），特立帕肽组：0.021（0.044），=0.191）在特立帕肽组中趋于更高，尽管差异无统计学意义。与双膦酸盐和未接受药物治疗相比，特立帕肽增加了 2 型糖尿病骨质疏松症患者的股骨颈和 TBS 的 BMD。
